Stratec SESRBZF 67 EBIT per Share is $0.56 as of Mar. 2026. GuruFocus rates SRBZF with a GF Score™ of 67/100 and a GF Value™ of $124.22. The stock has 5 warning signs investors should review. Among 688 Medical Devices & Instruments companies, Stratec SE ranks worse than 92.73% on this metric.
Stratec SE's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.56.
During the past 12 months, the average EBIT per Share Growth Rate of Stratec SE was -74.70% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -37.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -20.30% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -0.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Stratec SE's EBIT per Share or its related term are showing as below:
SRBZF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -37 Med: 1 Max: 67.1
Current: -37
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Stratec SE was 67.10% per year. The lowest was -37.00% per year. And the median was 1.00% per year.
SRBZF's 3-Year EBIT Growth Rate is ranked worse than 92.73% of 688
companies
in the Medical Devices & Instruments industry
Industry Median: 9.5
vs SRBZF: -37.00
Stratec SE's EBIT for the
three
months ended in Mar. 2026 was $-0.2 Mil.
Stratec SE (OTCPK:SRBZF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Stratec SE EBIT per Share Related Terms
Stratec SE EBIT per Share Historical Data
* Premium members only.
The historical data trend for Stratec SE's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.56
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stratec SE (SRBZF) has a EBIT per Share of $0.56 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Stratec SE and its competitors. According to the industry distribution chart, Stratec SE ranks #638 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 92.7%.
Is Stratec SE's EBIT per Share too high?
Stratec SE's current EBIT per Share is $0.56. The Medical Devices & Instruments industry median EBIT per Share is 9.50. Stratec SE's value of $0.56 is 94.1% below this industry median. Based on the distribution chart, Stratec SE ranks #638 out of 688 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Stratec SE has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Stratec SE's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Stratec SE ranks #638 out of 688 companies for EBIT per Share. This places Stratec SE in the lower half of its industry. The industry median EBIT per Share is 9.50. Stratec SE's value of $0.56 is 94.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.50, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stratec SE's current EBIT per Share of $0.56 is 94.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Stratec SE and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stratec SE's current EBIT per Share is $0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stratec SE stock overvalued right now?
Stratec SE (SRBZF) has a current EBIT per Share of $0.56. The stock's GF Value™ is $124.22, compared to a current price of $72.96 — trading 41.3% below its estimated fair value. The current EBIT per Share is $0.56 and 94.1% below the Medical Devices & Instruments industry median of 9.50. Stratec SE's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Stratec SE (SRBZF), the current EBIT per Share is $0.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stratec SE (SRBZF) Overvalued in 2026?
Based on GuruFocus' analysis, Stratec SE stock appears to be undervalued.
The current stock price of $72.96 is trading 41.3% below its estimated GF Value™ of $124.22.
Key valuation signals for SRBZF:
EBIT per Share: $0.56
GF Value™: $124.22 vs. price of $72.96 (41.3% below fair value)
Industry Position: 94.1% below the Medical Devices & Instruments median (#638 of 688)
No single metric tells the full story. See the SRBZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stratec SE designs and manufactures automation solutions for regulated laboratory markets. STRATEC acts as an OEM partner to players in the in-vitro diagnostics and life sciences markets. The Group's product range includes both hardware solutions, software solutions, and related consumables, as well as independently marketed consumables. These products are mostly combined into fully integrated system solutions and often receive market approval together with partners' reagents.
67GF Score
Get the complete analysis for SRBZF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRBZF has been successfully added to your 
